(Q54506169)

English

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

1 reference

based on heuristic

inferred from title

author name string

L K Hicks

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

A Woods

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

R Buckstein

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

J Mangel

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

N Pennell

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

L Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

K Imrie

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

D Spaner

8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

M C Cheung

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

A Boudreau

10

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

M Reis

11

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

M Crump

12

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

N L Berinstein

13

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

language of work or name

0 references

publication date

24 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

43

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

701-708

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

21 January 2018

High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

21 January 2018

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of minimal residual disease by polymerase chain reaction in B cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Phenotype of recovering lymphoid cell populations after marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Interstitial pneumonitis related to rituximab therapy.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.382

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2008.382

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/19029963

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54506169&oldid=2212492753"